TFF Pharmaceuticals announced that the company has raised $25.9 million in a private placement, with the funds to be used to “to accelerate the expansion of the company’s internal development portfolio beyond its programs for voriconazole and tacrolimus inhalation powders.”
Earlier this year, the company announced that it was working on a universal flu vaccine in partnership with two US universities and that it had signed an agreement with the US military for development of dry powder vaccines. TFF’s pipeline also includes a triple combination DPI for the treatment of asthma and COPD and a dry powder nicolsamide.
TFF Pharmaceuticals President and CEO Glenn Mattes commented, “Today’s significant financing, by these quality healthcare institutional investors, underlines our commitment to bring our advanced technology to improve drug delivery, and will allow us to accelerate and advance our internal development pipeline. Our ability to secure this transaction is a strong validation of our Thin Film Freezing technology platform and reflects our track record in meeting internal development milestones, as well as our active business development and partnering efforts.”
Read the TFF Pharmaceuticals press release.
